- Home
- NAGE vs CCAP Comparison
NAGE vs CCAP Comparison
Compare NAGE & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAGE | CCAP |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 531.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAGE | CCAP |
|---|---|---|
| Price | $4.93 | $13.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.33 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 732.8K | 157.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.20% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.37 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | $21.29 | ★ $14.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $13.03 |
| 52 Week High | $14.66 | $19.14 |
Technical Indicators
Market Signals| Indicator | NAGE | CCAP |
|---|---|---|
| Relative Strength Index (RSI) | 26.98 | 33.36 |
| Support Level | $4.93 | $13.69 |
| Resistance Level | $5.32 | $14.51 |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 5.60 | 10.34 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About CCAP Crescent Capital BDC Inc.
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.